Myoclonus: Pathophysiology and Treatment Options

Area of Science:

• Neurology
• Pharmacology

Background:

• Myoclonus treatment necessitates understanding its diverse physiopathology.
• Initial steps involve identifying epileptic components and reversible iatrogenic causes.

Purpose of the Study:

• To outline a systematic approach to myoclonus treatment based on its underlying generator.
• To detail first-line and alternative pharmacological interventions for different myoclonus types.

Main Methods:

• Review of current literature on myoclonus pathophysiology and treatment strategies.
• Categorization of myoclonus based on generator location (cortical, subcortical, brainstem, spinal).
• Analysis of medication efficacy and potential adverse effects for each category.

Main Results:

• Cortical myoclonus: levetiracetam, valproic acid, clonazepam are first-line; phenytoin/carbamazepine may worsen it.
• Subcortical/brainstem myoclonus: clonazepam is first-line; levetiracetam/valproic acid are alternatives.
• Spinal myoclonus: refractory to anti-epileptics; clonazepam is first-line; botulinum toxin for focal cases.
• Propriospinal/functional myoclonus: requires multidisciplinary approach with psychotropics and therapy.

Conclusions:

• Treatment selection for myoclonus depends critically on accurate diagnosis of the generator.
• A stepwise approach, considering epilepsy, iatrogenic causes, and generator location, optimizes therapeutic outcomes.
• Multidisciplinary care is essential for complex or functional myoclonus presentations.